董事
Gary W. Pace, Ph.D., is an experienced biopharmaceutical executive and director who serves as an independent director of Cardiff Oncology, Inc. (CRDF) and chair of the company’s Corporate Governance and Nominating Committee.[[9]](https://investors.cardiffoncology.com/board-member/gary-w-pace/)[[10]](https://cardiffoncology.com/board-of-directors/) He has been a director of Cardiff Oncology since April 2020 and is a significant shareholder through a combination of direct holdings, indirect holdings via a minor child, and stock option grants reported in recent SEC Form 4 filings.[[1]](https://www.marketscreener.com/insider/GARY-PACE-A02P46/)[[6]](https://www.investing.com/news/insider-trading-news/cardiff-oncology-director-gary-pace-buys-940199-in-stock-93CH-3769996)[[7]](https://www.stocktitan.net/sec-filings/CRDF/form-4-cardiff-oncology-inc-insider-trading-activity-1eefd07518b8.html)[[8]](https://www.sec.gov/Archives/edgar/data/1184778/000095017025100882/xslF345X05/ownership.xml) In these filings, he is identified as a director and reporting person for insider transactions in Cardiff Oncology common stock.[[3]](https://www.insiderinsights.com/free/index.php?s=filer&o=-1&a=&q=PACE+GARY+W)[[8]](https://www.sec.gov/Archives/edgar/data/1184778/000095017025100882/xslF345X05/ownership.xml)
Pace has held numerous senior leadership and board roles across the life sciences sector, including founder of Transcend Therapeutics, Inc. and Sova Pharmaceuticals, Inc., former Chairman and CEO of Waratah Pharmaceuticals, Inc., and former President and CEO of SkyePharma Canada, Inc.[[1]](https://www.marketscreener.com/insider/GARY-PACE-A02P46/) He previously served as an independent director at ResMed Inc., Pacira BioSciences, Inc., Transition Therapeutics, Inc., and several other medical and biotechnology companies, and he currently holds roles such as Executive Chairman of View Point Medical, Inc. and director or partner in multiple health technology ventures.[[1]](https://www.marketscreener.com/insider/GARY-PACE-A02P46/)[[5]](https://theorg.com/org/pacira-pharmaceuticals/org-chart/gary-w-pace) Pace earned his doctorate from the Massachusetts Institute of Technology in 1975 and an undergraduate degree from the University of New South Wales in 1974, providing a scientific foundation for his long career in pharmaceutical R&D, corporate leadership, and board governance.[[1]](https://www.marketscreener.com/insider/GARY-PACE-A02P46/)
查看完整内部人档案 →